Inogen vs Staar Surgical
Inogen is the larger business, with $349m of revenue in fiscal 2025 against $239m for Staar Surgical (1.5 times as much). Inogen grew faster (3.9% against -23.7%). Inogen kept more of each dollar of sales as profit: a net margin of -6.5% against -33.6%. Inogen carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | InogenINGN, 2025 | Staar SurgicalSTAA, 2025 |
|---|---|---|
| Revenue | $349m | $239m |
| Revenue growth | 3.9% | -23.7% |
| Net income | −$22.7m | −$80.4m |
| Operating margin | -8.7% | -38.3% |
| Net margin | -6.5% | -33.6% |
| Return on equity | -12.4% | -21.7% |
| Free cash flow | −$13.7m | −$40.0m |
| Cash | $104m | $153m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $6.5m |
| Employees | — | 957 |
| Market value | $186m | $1.25bn |
| Price vs our value range | — | — |
| Moat score | 41 (Weak) | 34 (Weak) |
| Insider trades, 12 months | 0 buys, 2 sales | 21 buys, 0 sales |